Immucell (ICCC)

The company’s main product line is First Defense, which is based on hyperimmunized bovine colostrum. The product is given orally to newborn calves and is designed to deliver targeted antibodies against major causes of neonatal calf diarrhea, commonly known as scours. These pathogens include Escherichia coli, bovine coronavirus and bovine rotavirus. By focusing on the earliest hours of a calf’s life, ImmuCell addresses a critical period for producers, when disease prevention can affect mortality, veterinary costs, weight gain and future productivity.

ImmuCell reports its business around two areas: Scours and Mastitis. The Scours segment, driven by the First Defense family of products, accounts for most of the company’s revenue. The Mastitis segment reflects the company’s broader interest in biologically based solutions for dairy cow health, an important issue for milk quality, animal welfare and farm economics.

Unlike diversified animal health multinationals, ImmuCell is a more focused specialist with a narrow product base and manufacturing-driven operating model. Its performance is tied to cattle industry demand, producer adoption, distribution relationships, regulatory requirements and the company’s ability to scale biological production reliably.